The facility is designed for large-scale cell culture manufacturing of bulk drug substance production with eight 20,000L bioreactors. But the facility could be expanded to accommodate up to 24 more 20,000L bioreactors based on market demand, for a potential total of 32, Fujifilm Diosynth Biotechnologies CEO Martin Meeson told GEN Edge

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge